收藏切换
Impact of PD-1 inhibitor therapy on population incremental health outcome gain for patients with esophageal squamous cell carcinoma in China
收藏切换
Jiahua LENG1, 2, Ziyi LIN3, Jianwei XUAN3, *
World Clinical Drug | 2023, 44(1) : 51 - 58
Less
收藏切换
World Clinical Drug | 2023, 44(1): 51-58
• Article •
Impact of PD-1 inhibitor therapy on population incremental health outcome gain for patients with esophageal squamous cell carcinoma in China
Full
Jiahua LENG1, 2, Ziyi LIN3, Jianwei XUAN3, *
Affiliations
  • 1.Department of GI Cancer Center Surgery Unit Ⅲ, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China
  • 2.Medical Insurance Department, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China
  • 3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China
Published: 2023-01-10 doi: 10.13683/j.wph.2023.01.009
Outline
收藏切换
Objective

To estimate the potential health benefits of pembrolizumab for the second-line esophageal squamous cell carcinoma patients with programmed death-ligand 1 positive [combined positive score (CPS)≥10] in China from 2021 to 2025, in order to provide reference for scientific evaluation of clinical benefits of innovative antitumor drugs and effective allocation of health resources.

Methods

A patient flow calculation model and a partitioned survival model were built to calculate the number of patients with second-line esophageal squamous cell carcinoma who might be treated with pembrolizumab from 2021 to 2025. A partitioned survival model was established to estimate the incremental benefits of life year (LY) and quality-adjusted life years (QALYs) gained of an average patient using pembrolizumab compared with regular chemotherapies. The total potential gains in LY and QALYs of the second-line esophageal squamous cell carcinoma patients in China from 2021 to 2025 was calculated by discounting at 5% annually.

Results

In the next 5 years, a total of 43 439 patients could benefit from pembrolizumab. The average lifetime LY and QALYs increments per patient with pembrolizumab are 1.603 and 1.442, respectively. The total increments of LY and QALYs in 5 years gained by the introduction of pembrolizumab were 63 026 and 56 696, respectively.

Conclusions

Programmed death-1 inhibitor is expected to bring considerable survival and quality-of-life benefits for patients with esophageal squamous cell carcinoma in China.

PD-1 inhibitor  /  pembrolizumab  /  esophageal squamous cell carcinoma  /  quality-adjusted life year
冷家骅, 林子义, 宣建伟. PD-1抑制剂免疫治疗对中国食管鳞癌患者的潜在健康产出探索. 世界临床药物, 2023 , 44 (1) : 51 -58 . DOI: 10.13683/j.wph.2023.01.009
Jiahua LENG, Ziyi LIN, Jianwei XUAN. Impact of PD-1 inhibitor therapy on population incremental health outcome gain for patients with esophageal squamous cell carcinoma in China[J]. World Clinical Drug, 2023 , 44 (1) : 51 -58 . DOI: 10.13683/j.wph.2023.01.009
Year 2023 volume 44 Issue 1
10
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.01.009
  • Receive Date:2022-10-20
  • Online Date:2026-11-18
  • Published:2023-01-10
Article Data
Affiliations
History
  • Received:2022-10-20
Affiliations
    1.Department of GI Cancer Center Surgery Unit Ⅲ, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China
    2.Medical Insurance Department, Key laboratory of Carcinogenesis and Translational Research, Peking University Cancer Hospital & Institute, Beijing 100142, China
    3.Health Economics Research Institute, School of Pharmaceutical Sciences, Sun yat-sen University, Guangzhou 510006, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.01.009
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT